Portopulmonary hypertension (PoPH) is a poorly understood complication of liver disease which affects about 10% of patients with pulmonary hypertension. This case report outlines the difficulties in ...

Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a long-acting calcium ...

Idorsia gets FDA approval of Tryvio (aprocitentan) for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that use.

Dysfunctional Voltage-Gated K + Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension ...

Krowka MJ et al. (2004) Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 10: 174–182 Article Google Scholar ...

The UK medicines regulator has awarded Alnylam's RNAi-based therapy zilebesiran for hypertension an 'innovation passport', a designation designed to speed up NHS access to promising new medicines ...